Novo Nordisk opens new research centre in Seattle

22-Sep-2009 - USA

Novo Nordisk announced the official opening of the company’s new inflammation research centre based in Seattle. The research centre will leverage Novo Nordisk’s strong knowledge within the field of proteins, in order to further build the company’s clinical pipeline of products for the treatment of chronic inflammatory diseases. Novo Nordisk currently has four projects in early clinical development within the field of inflammation in rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus.

“Seattle is a biotech centre of excellence, and placing our inflammation research centre here allows us to attract top scientists and collaborate with high quality partners,” said Mads Krogsgaard Thomsen, Novo Nordisk’s chief science officer. “By investing in early stage research we hope to find the underlying causes for different inflammatory conditions and develop new treatments for these diseases.”

Novo Nordisk announced its plans to create a new research centre in Seattle in August 2008 and has assembled a highly skilled management team led by Don Foster, vice president of inflammation. It is planned that the centre will have a total of 60 employees by the end of 2010. Research activities in Seattle will complement continuing biopharmaceutical research activities in Novo Nordisk’s research sites in Måløv in Denmark and Beijing in China.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems

Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems

Triple-threat cancer-fighting polymer capsules for guided drug delivery created

Triple-threat cancer-fighting polymer capsules for guided drug delivery created

Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells - New approach could dramatically improve the success rate of immune-cell therapies

Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

Scientists identify a candidate gene for osteoporosis - Gene may underlie differences between African Americans and Caucasians

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

A better route to benzocyclobutenes, sought-after buildingblocks for drugs - Scripps Research chemists devise a new, C-H activation-based method for the synthesis of BCBs

A better route to benzocyclobutenes, sought-after buildingblocks for drugs - Scripps Research chemists devise a new, C-H activation-based method for the synthesis of BCBs

CT Atlantic AG Announces Appointment of Michael Höcker to CEO - Cara Lerner joins CT Atlantic as COO

Rentschler Expands Single-Use Manufacturing Capacities

BioOutsource Opens New Facility in Glasgow - Double’s the Company’s Capacity for Biologics Contract Testing and Biosimilar Characterisation

Scientists reveal changes to embryonic stem cells caused by Down syndrome

MIT researchers discover an unexpected twist in cancer metabolism - Cancer-cell quirk could be exploited to develop new drugs that starve tumors